Superactivated platelets: Thrombus regulators, thrombin generators, and potential clinical targets

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 8, 2013, Pages 1747-1752

  Mazepa, Marshall ^a   Hoffman, Maureane ^b   Monroe, Dougald ^c  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

activation; Hemostasis; Phosphatidylserine; Platelet; Procoagulant

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CALCIUM; CYCLOPHILIN D; CYCLOSPORIN; FIBRINOGEN; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; UBIQUINONE;

BLOOD CLOT RETRACTION; CALCIUM CELL LEVEL; CAROTID ARTERY OBSTRUCTION; CELL SUBPOPULATION; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; THROMBOCYTOPOIESIS; THROMBOSIS; THROMBUS;

ACTIVATION; HEMOSTASIS; PHOSPHATIDYLSERINE; PLATELET; PROCOAGULANT;

ANIMALS; BLOOD PLATELETS; HEMOSTASIS; HUMANS; PLATELET ACTIVATION; THROMBIN; THROMBOSIS;

EID: 84881012996     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301790     Document Type: Review

References (45)

1. Sixma JJ, Wester J. The hemostatic plug. Semin Hematol. 1977;14: 265-299.
2. Sixma JJ, Kater L, Bouma BN, Schmitz du Moulin F, De Graaf S, Tuit G. Immunofluorescent localization of factor VIII-related antigen, fibrinogen, and several other plasma proteins in hemostatic plugs in humans. J Lab Clin Med. 1976;87: 112-119.
3. Wester J, Sixma JJ, Geuze JJ, Heijnen HF. Morphology of the hemostatic plug in human skin wounds: transformation of the plug. Lab Invest. 1979;41: 182-192.
4. Munnix IC, Kuijpers MJ, Auger J, Thomassen CM, Panizzi P, van Zandvoort MA, Rosing J, Bock PE, Watson SP, Heemskerk JW. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol. 2007;27: 2484-2490.
5. Shi J, Pipe SW, Rasmussen JT, Heegaard CW, Gilbert GE. Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure. J Thromb Haemost. 2008;6: 1167-1174.
6. Jobe SM, Wilson KM, Leo L, Raimondi A, Molkentin JD, Lentz SR, Di Paola J. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood. 2008;111: 1257-1265.
7. Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin αIIbβ3 adhesive function and thrombus growth. J Biol Chem. 2004;279: 30697-30706.
8. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000;95: 1694-1702.
9. Nieswandt B, Bergmeier W, Schulte V, Rackebrandt K, Gessner JE, Zirngibl H. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain. J Biol Chem. 2000;275: 23998-24002.
10. Leo L, Di Paola J, Judd BA, Koretzky GA, Lentz SR. Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen. Blood. 2002;100: 2839-2844.
11. Jobe SM, Leo L, Eastvold JS, Dickneite G, Ratliff TL, Lentz SR, Di Paola J. Role of FcRgamma and factor XIIIA in coated platelet formation. Blood. 2005;106: 4146-4151.
12. Fager AM, Wood JP, Bouchard BA, Feng P, Tracy PB. Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase. Arterioscler Thromb Vasc Biol. 2010;30: 2400-2407.
13. Batar P, Dale GL. Simultaneous engagement of thrombin and FcγRIIA receptors results in platelets expressing high levels of procoagulant proteins. J Lab Clin Med. 2001;138: 393-402.
14. van der Meijden PE, Feijge MA, Giesen PL, Huijberts M, van Raak LP, Heemskerk JW. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost. 2005;93: 1128-1136.
15. Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood. 1997;90: 2615-2625.
16. Luik RM, Wang B, Prakriya M, Wu MM, Lewis RS. Oligomerization of STIM1 couples ER calcium depletion to CRAC channel activation. Nature. 2008;454: 538-542.
17. Gilio K, van Kruchten R, Braun A, Berna-Erro A, Feijge MA, Stegner D, van der Meijden PE, Kuijpers MJ, Varga-Szabo D, Heemskerk JW, Nieswandt B. Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation. J Biol Chem. 2010;285: 23629-23638.
18. Remenyi G, Szasz R, Friese P, Dale GL. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol. 2005;25: 467-471.
19. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009;114: 663-666.
20. Dale GL, Friese P. Bax activators potentiate coated-platelet formation. J Thromb Haemost. 2006;4: 2664-2669.
21. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta. 1983;736: 57-66.
22. Bevers EM, Comfurius P, Zwaal RF. The nature of the binding for prothrombinase at the platelet surface as revealed by lipolytic enzymes. Eur J Biochem. 1982;122: 81-85.
23. Bevers EM, Comfurius P, van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem. 1982;122: 429-436.
24. Brooks MB, Catalfamo JL, Friese P, Dale GL. Scott syndrome dogs have impaired coated-platelet formation and calcein-release but normal mitochondrial depolarization. J Thromb Haemost. 2007;5: 1972-1974.
25. Majumder R, Quinn-Allen MA, Kane WH, Lentz BR. The phosphatidylserine binding site of the factor Va C2 domain accounts for membrane binding but does not contribute to the assembly or activity of a human factor Xa-factor Va complex. Biochemistry. 2005;44: 711-718.
26. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, Clemetson KJ, Alberio L. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415: 175-179.
27. Panteleev MA, Ananyeva NM, Greco NJ, Ataullakhanov FI, Saenko EL. Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex. J Thromb Haemost. 2005;3: 2545-2553.
28. Kempton CL, Hoffman M, Roberts HR, Monroe DM. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol. 2005;25: 861-866.
29. Maroney SA, Haberichter SL, Friese P, Collins ML, Ferrel JP, Dale GL, Mast AE. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood. 2007;109: 1931-1937.
30. Maroney SA, Cooley BC, Ferrel JP, Bonesho CE, Mast AE. Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth. Arterioscler Thromb Vasc Biol. 2011;31: 821-826.
31. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3: 2185-2192.
32. Prodan CI, Vincent AS, Padmanabhan R, Dale GL. Coated-platelet levels are low in patients with spontaneous intracerebral hemorrhage. Stroke. 2009;40: 2578-2580.
33. Prodan CI, Vincent AS, Dale GL. Coated platelet levels correlate with bleed volume in patients with spontaneous intracerebral hemorrhage. Stroke. 2010;41: 1301-1303.
34. Prodan CI, Stoner JA, Cowan LD, Dale GL. Lower coated-platelet levels are associated with early hemorrhagic transformation in patients with nonlacunar brain infarction. J Thromb Haemost. 2010;8: 1185-1190.
35. Prodan CI, Dale GL. Coated-platelets in ischemic stroke - potential insight into the etiology of stroke subtypes. Int J Stroke. 2008;3: 249-250.
36. Prodan CI, Vincent AS, Dale GL. Coated-platelet levels are elevated in patients with transient ischemic attack. Transl Res. 2011;158: 71-75.
37. Saxena K, Pethe K, Dale GL. Coated-platelet levels may explain some variability in clinical phenotypes observed with severe hemophilia. J Thromb Haemost. 2010;8: 1140-1142.
38. van Kruchten R, Braun A, Feijge MA, Kuijpers MJ, Rivera-Galdos R, Kraft P, Stoll G, Kleinschnitz C, Bevers EM, Nieswandt B, Heemskerk JW. Antithrombotic potential of blockers of store-operated calcium channels in platelets. Arterioscler Thromb Vasc Biol. 2012;32: 1717-1723.
39. Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost. 2007;5: 774-780.
40. Knudsen T, Kjalke M, Tranholm M, Nichols TC, Jensen AL, Kristensen AT. Development of a flow cytometric assay for detection of coated platelets in dogs and evaluation of binding of coated platelets to recombinant human coagulation factor VIIa. Am J Vet Res. 2011;72: 1007-1014.
41. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99: 542-547.
42. Hoffman M, Volovyk Z, Persson E, Gabriel DA, Ezban M, Monroe DM. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. J Thromb Haemost. 2011;9: 759-766.
43. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11: 1149-1159.
44. Vogler M, Hamali HA, Sun X-M, et al. BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood. 2010;117: 7145-7154.
45. Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118: 1663-1674.